



Berkshire West Area Prescribing Committee (BWAPC)

Berkshire West Area Prescribing Committee Policy Statement

Drug Name	Aripiprazole long acting injection (LAI) (Abilify Maintena®)	
Indication under review	Schizophrenia	
Policy No:	APC 083	
Date of Issue:	September 2014	
Review Date:	September 2017	
Policy Statement: Aripiprazole LAI (Abilify Maintena®) is recommended as the first line treatment for patients who are stabilised on oral aripiprazole but have become non concordant.		
Traffic Light Status	Amber	
Key Points considered: <ul style="list-style-type: none"> • Treatment should always be initiated within secondary care. • Aripiprazole LAI (Abilify Maintena®) (400mg/month) has been shown to be non-inferior to oral aripiprazole (10-30mg/day) in terms of relapse rates or efficacy. • The adverse effect profile Aripiprazole LAI (Abilify Maintena®) is favorable especially in comparison with other 1st generation and 2nd generation antipsychotics. • Aripiprazole LAI (Abilify Maintena®) requires reconstitution and is only available in one size. The dosing schedule is 400mg every month, with the option of 300mg for lower doses. • Aripiprazole LAI (Abilify Maintena®) does not require refrigeration and can be administered in calendar months (i.e. not 4 weekly). • The option of using Aripiprazole LAI (Abilify Maintena®) should only be considered for patients who are clearly non-concordant (shown by frequent relapse) or patient choice. 		
References: <ol style="list-style-type: none"> 1. Kane, J.M.et al. J Clin Psych 73:5 May 2012 2. Wolfgang Fleischhacker, W., et al. Supplied by Otsuka representative. 3. Kane, J.M., et al. Journal of Medical Economics; 16/7. 2013, 917-925. 		
Date taken to APC:	3 rd September 2014	
Date Ratified by MMC on Behalf of the Board:	8 th October 2014	